Figure S7 from LncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity

Figure S7 from LncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity

<p>Figure S7</p>

Bewaard in:

Bibliografische gegevens
Hoofdauteur:	Shiyi Yu (17079079) (author)
Andere auteurs:	Ying Wang (17079082) (author), Xue Gong (17079085) (author), Zhehao Fan (17079088) (author), Zheng Wang (17079091) (author), Zhengyan Liang (17079094) (author), Rui Wu (17079097) (author), Binjie Cao (17079100) (author), Ning Wang (17079103) (author), Caili Bi (17079106) (author), Dan Lv (17079109) (author), Haibo Sun (17079112) (author)
Gepubliceerd in:	2025
Onderwerpen:	Cancer Molecular and Cellular Biology Therapeutic Research and Development Breast Cancer Cell Cycle Signal transduction pathways Drug Resistance Regulation of gene expression in drug resistance Endocrine-Related Cancers
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items

Figure S1 from LncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity
door: Shiyi Yu (17079079)
Gepubliceerd in: (2025)

Figure S2 from LncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity
door: Shiyi Yu (17079079)
Gepubliceerd in: (2025)

Figure S3 from LncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity
door: Shiyi Yu (17079079)
Gepubliceerd in: (2025)

Figure S4 from LncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity
door: Shiyi Yu (17079079)
Gepubliceerd in: (2025)

Figure S5 from LncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity
door: Shiyi Yu (17079079)
Gepubliceerd in: (2025)

Figure S6 from LncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity
door: Shiyi Yu (17079079)
Gepubliceerd in: (2025)

Figure S8 from LncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity
door: Shiyi Yu (17079079)
Gepubliceerd in: (2025)

Supplementary Figure 7 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
door: Seung Yeon Oh (15051017)
Gepubliceerd in: (2025)

Supplementary Table S1 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
door: Yufang Bao (15386826)
Gepubliceerd in: (2025)

Supplementary Table S2 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
door: Yufang Bao (15386826)
Gepubliceerd in: (2025)

Supplementary Table S3 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
door: Yufang Bao (15386826)
Gepubliceerd in: (2025)

Supplementary Table S4 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
door: Yufang Bao (15386826)
Gepubliceerd in: (2025)

Supplementary Table S5 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
door: Yufang Bao (15386826)
Gepubliceerd in: (2025)

Table ST7 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
door: Ossia M. Eichhoff (14964145)
Gepubliceerd in: (2025)

Supplementary Table from CircIPO7 Promotes Nasopharyngeal Carcinoma Metastasis and Cisplatin Chemoresistance by Facilitating YBX1 Nuclear Localization
door: Xiaohong Hong (22681698)
Gepubliceerd in: (2025)

Supplementary Table S1 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer
door: Nicole A. Traphagen (16677391)
Gepubliceerd in: (2025)

Supplementary Table S2 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer
door: Nicole A. Traphagen (16677391)
Gepubliceerd in: (2025)

Data file S1 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
door: Alex C.H. Liu (14961921)
Gepubliceerd in: (2025)

Data file S2 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
door: Alex C.H. Liu (14961921)
Gepubliceerd in: (2025)

Data file S3 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
door: Alex C.H. Liu (14961921)
Gepubliceerd in: (2025)

Data file S4 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
door: Alex C.H. Liu (14961921)
Gepubliceerd in: (2025)

Data file S5 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
door: Alex C.H. Liu (14961921)
Gepubliceerd in: (2025)

Table S1 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
door: Alex C.H. Liu (14961921)
Gepubliceerd in: (2025)

Supplementary Figure 1 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
door: Seung Yeon Oh (15051017)
Gepubliceerd in: (2025)

Supplementary Figure 10 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
door: Seung Yeon Oh (15051017)
Gepubliceerd in: (2025)

Supplementary Figure 2 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
door: Seung Yeon Oh (15051017)
Gepubliceerd in: (2025)

Supplementary Figure 3 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
door: Seung Yeon Oh (15051017)
Gepubliceerd in: (2025)

Supplementary Figure 4 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
door: Seung Yeon Oh (15051017)
Gepubliceerd in: (2025)

Supplementary Figure 5 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
door: Seung Yeon Oh (15051017)
Gepubliceerd in: (2025)

Supplementary Figure 6 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
door: Seung Yeon Oh (15051017)
Gepubliceerd in: (2025)

Supplementary Figure 8 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
door: Seung Yeon Oh (15051017)
Gepubliceerd in: (2025)

Supplementary Figure 9 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
door: Seung Yeon Oh (15051017)
Gepubliceerd in: (2025)

Supplementary Table 1 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
door: Seung Yeon Oh (15051017)
Gepubliceerd in: (2025)

Supplementary Table 2 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
door: Seung Yeon Oh (15051017)
Gepubliceerd in: (2025)

Supplementary Data from <i>N</i><sup>6</sup>-methyladenosine Modification of FZR1 mRNA Promotes Gemcitabine Resistance in Pancreatic Cancer
door: Jiachun Su (16990970)
Gepubliceerd in: (2025)

Supplementary Data S7 from Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors
door: Naoual Menssouri (16617248)
Gepubliceerd in: (2025)

Supplementary Table S7 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
door: Laura E. Stevens (14961009)
Gepubliceerd in: (2025)

Figure S1 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
door: Dahihm Kim (16546203)
Gepubliceerd in: (2025)

Figure S2 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
door: Dahihm Kim (16546203)
Gepubliceerd in: (2025)

Figure S3 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
door: Dahihm Kim (16546203)
Gepubliceerd in: (2025)

Cannot write session to /tmp/vufind_sessions/sess_5pjmcv6lm29jp9ohhs4ioms6ej